Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Algernon Pharmaceuticalsinc (AGN.CN)

Algernon Pharmaceuticalsinc (AGN.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,068
  • Shares Outstanding, K 2,413
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,054 K
  • 60-Month Beta -1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.14
Trade AGN.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -3.55
  • Most Recent Earnings -0.79 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

    TSX Bottom 100 Stocks

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.9700 +6.60%
on 02/02/23
2.3500 -10.64%
on 01/04/23
-0.2000 (-8.70%)
since 01/03/23
3-Month
1.9700 +6.60%
on 02/02/23
3.2400 -35.19%
on 11/09/22
-0.4400 (-17.32%)
since 11/03/22
52-Week
1.9700 +6.60%
on 02/02/23
7.8300 -73.18%
on 02/08/22
-5.2100 (-71.27%)
since 02/03/22

Most Recent Stories

More News
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 2.1000 (unch)
AGNPF : 1.6500 (+4.43%)
The Power Play by The Market Herald Releases New Interviews with First Mining Gold Corp., Algernon Pharmaceuticals, G Mining Ventures, ApartmentLove, and Orvana Minerals

VANCOUVER, BC / ACCESSWIRE / July 18, 2022 / The Power Play by The Market Herald has announced the release of new interviews with First Mining Gold Corp., Algernon Pharmaceuticals, G Mining Ventures, ApartmentLove,...

FF.TO : 0.2050 (unch)
AGN.CN : 2.1000 (unch)
GMIN.VN : 0.890 (-1.11%)
APLV.CN : 0.1150 (-4.17%)
ORV.TO : 0.1850 (-2.63%)
Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 2.1000 (unch)
AGNPF : 1.6500 (+4.43%)
The Power Play by The Market Herald Releases New Interviews with K9 Gold, Algernon Pharmaceuticals, Deep-South Resources, and Saturn Oil & Gas

VANCOUVER, BC / ACCESSWIRE / July 7, 2022 / The Power Play by The Market Herald has announced the release of new interviews with K9 Gold, Algernon Pharmaceuticals, Deep-South Resources, and Saturn Oil...

KNC.VN : 0.065 (unch)
AGN.CN : 2.1000 (unch)
DSM.VN : 0.065 (-7.14%)
SOIL.VN : 2.390 (-0.42%)
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 2.1000 (unch)
AGNPF : 1.6500 (+4.43%)
Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

VANCOUVER, British Columbia, July 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 2.1000 (unch)
AGNPF : 1.6500 (+4.43%)
Algernon Pharmaceuticals Announces Closing of Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 04, 2022 (GLOBE NEWSWIRE) --...

AGN.CN : 2.1000 (unch)
AGNPF : 1.6500 (+4.43%)
Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) --...

AGN.CN : 2.1000 (unch)
AGNPF : 1.6500 (+4.43%)
Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) --...

AGN.CN : 2.1000 (unch)
AGNPF : 1.6500 (+4.43%)
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...

AGN.CN : 2.1000 (unch)
AGNPF : 1.6500 (+4.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 2.2667
2nd Resistance Point 2.2333
1st Resistance Point 2.1667
Last Price 2.1000
1st Support Level 2.0667
2nd Support Level 2.0333
3rd Support Level 1.9667

See More

52-Week High 7.8300
Fibonacci 61.8% 5.5915
Fibonacci 50% 4.9000
Fibonacci 38.2% 4.2085
Last Price 2.1000
52-Week Low 1.9700

See More

Business Summary

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar